CYT387: Interim Phase I/II data

YM reported additional data from an ongoing Phase I/II trial of once-daily oral CYT387 in patients with myelofibrosis. In 22 patients evaluable for an anemia response, defined as baseline hemoglobin of 10 g/dL or red blood cell transfusion-dependency, CYT387 produced a total anemia response rate of 63%, with 9 patients achieving "Clinical Improvement" per International Working Group for Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria. In 30 evaluable patients with splenomegaly at baseline (median 20 cm), CYT387 led to a reduction in spleen size in 29 patients (median 9 cm), with 11 patients achieving a >=50% reduction in palpable spleen size. The MTD was once-daily 300 mg CYT387. Data were presented at the American Society of Hematology meeting in Orlando. ...